Xtrackers美元非投资等级公司债券ETF HYLB 深 沪
等待开盘 01-15 09:30:00 美东时间
36.985
-0.035
-0.09%
华盛通- 最 高37.005
- 今 开36.985
- 成交量 80.38万股
- 最 低 36.97
- 昨 收 37.02
- 总市值 39.20亿
- 52周最高 37.05
- 市盈率 静 --
- 换手率 0.76%
- 52周最低 32.6391
- 委 比 -3.26%
- 总股本 1.06亿
- 历史最高 37.05
- 量 比 0.33
- 振 幅 0.09%
- 历史最低 18.4308
- 每 手 1
- 风险率 1.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, wit...
2025-12-15 20:00
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced th...
2025-12-01 20:00
RedHill Biopharma Receives Nasdaq Staff Determination Notification
On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity require...
2025-10-23 04:50
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership ...
2025-10-20 21:00
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill The New York Supreme Court unequivocally dismissed Kukbo Co. Ltd's ("Kukbo") defens...
2025-09-29 19:00
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: Recruitment initiated in th...
2025-09-05 19:00
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notif...
2025-04-18 04:01
RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: Global licensing deal (excludin...
2025-04-10 19:48
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK approval in Q4/25 Listed by AC...
2025-03-18 19:00
